| Přispěvatelé: |
[López,C, García,JA, Pinto,MJ, Oliver,B, Ortega,J, Suardíaz,M, Leyva,L] Research Laboratory, Clinical Neurosciences Institute, Hospital Universitario Carlos Haya and Fundación IMABIS, Málaga, Spain. [Fernández,O] Departament of Neurology, Clinical Neurosciences Institute, Hospital Regional Universitario Carlos Haya and Fundación IMABIS, Málaga, Spain. [Guijarro,C, Benito,J] Departament of Neurology, University Hospital 12 de Octubre, Madrid, Spain. [Benito,J] Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid. Spain. Department of Medicine, Complutense University, Madrid, Spain. [Prat,I] Transfusion Center Blood Bank, Málaga, Spain. [Varadé,J, Urcelay,E] Department of Immunology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain. [Álvarez,R] Department of Neurology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain. |
| Popis: |
The authors acknowledge the support from Fondo de Investigación Sanitaria & Fondo Europeo de Desarrollo Regional (PS09/01764) and Consejería de Salud de la Junta de Andalucía (SAS07/0231) to LL, and from Consejería de Innovación (P07-CTS-03223) to OF. The authors also thank the “Red Temática de Investigación Cooperativa Red Española de Esclerosis Múltiple REEM (RD07/0060/0019)” and Fundación Española de Esclerosis Múltiple (FEDEM). CLG is a holder of a fellowship from Consejería de Salud de la Junta de Andalucía (PI 0231-2007), MJPM is a holder of a FIS fellowship (PI 05/1878); JAGL and MS are holders of fellowships from Consejería de Innovación de la Junta de Andalucía (P07-0223). The TNF-related apoptosis inducing ligand (TRAIL)/TRAIL receptor system participates in crucial steps in immune cell activation or differentiation. It is able to inhibit proliferation and activation of T cells and to induce apoptosis of neurons and oligodendrocytes, and seems to be implicated in autoimmune diseases. Thus, TRAIL and TRAIL receptor genes are potential candidates for involvement in susceptibility to multiple sclerosis (MS). To test whether single-nucleotide polymorphisms (SNPs) in the human genes encoding TRAIL, TRAILR-1, TRAILR-2, TRAILR-3 and TRAILR-4 are associated with MS susceptibility, we performed a candidate gene case-control study in the Spanish population. 59 SNPs in the TRAIL and TRAIL receptor genes were analysed in 628 MS patients and 660 controls, and validated in an additional cohort of 295 MS patients and 233 controls. Despite none of the SNPs withstood the highly conservative Bonferroni correction, three SNPs showing uncorrected p values |
